Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.31 |
| ▸ | FDPS | P14324 | 4/20 | 0.30 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.30 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL850353 | 0.84 | SPHK1 (0.33) | LMNATSHRFDPSGPR84SPHK1 | |
| SCHEMBL16594112 | 0.80 | TSHR (0.34) | LMNATSHRFDPSGPR84SPHK1 | |
| SCHEMBL851466 | 0.74 | THRB (0.33) | LMNATSHRCA2 | |
| SCHEMBL27030494 | 0.74 | LMNA (0.32) | LMNATSHR | |
| SCHEMBL23600092 | 0.72 | LMNA (0.39) | LMNACA2DNM1FDPSGPR84 | |
| SCHEMBL28692993 | 0.72 | SPHK1 (0.39) | LMNACA2DNM1FDPSGPR84 | |
| SCHEMBL28954710 | 0.71 | LMNA (0.32) | LMNATSHRFDPSGPR84SPHK1 | |
| SCHEMBL30688673 | 0.71 | LMNA (0.32) | LMNATSHRFDPSGPR84SPHK1 | |
| SCHEMBL16594114 | 0.71 | LMNA (0.32) | LMNATSHRFDPSGPR84SPHK1 | |
| Ethylene Glycol SCHEMBL28428294 | 0.70 | LMNA (0.35) | LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383744-B2 | Actinically-crosslinkable siloxane-containing copolymers | NOVARTIS AG (CH) | 2013-02-26 | — | — | US | claimed |
| US-20100296049-A1 | ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS | ALCON INC. (CH) | 2010-11-25 | — | — | US | claimed |
| US-8383744-B2 | Actinically-crosslinkable siloxane-containing copolymers | NOVARTIS AG (CH) | 2013-02-26 | — | — | US | disclosed |
| US-20100296049-A1 | ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS | ALCON INC. (CH) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100296049-A1 | ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS | VCL, MACF1, CFL1 | LMNA 1029/4885TSHR 3589/4885CA2 3267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.